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Abstract
Background The 24-h area under the concentration–time curve (AUC 24)/minimal inhibitory concentration ratio is the best 
predictive pharmacokinetic/pharmacodynamic (PK/PD) parameter of the efficacy of first-line anti-tuberculosis (TB) drugs. 
An optimal sampling strategy (OSS) is useful for accurately estimating AUC 24; however, OSS has not been developed in the 
fed state or in the early phase of treatment for first-line anti-TB drugs.
Methods An OSS for the prediction of AUC 24 of isoniazid, rifampicin, ethambutol and pyrazinamide was developed for TB 
patients starting treatment. A prospective, randomized, crossover trial was performed during the first 3 days of treatment in 
which first-line anti-TB drugs were administered either intravenously or in fasting or fed conditions. The PK data were used 
to develop OSS with best subset selection multiple linear regression. The OSS was internally validated using a jackknife 
analysis and externally validated with other patients from different ethnicities and in a steady state of treatment.
Results OSS using time points of 2, 4 and 8 h post-dose performed best. Bias was < 5% and imprecision was < 15% for all 
drugs except ethambutol in the fed condition. External validation showed that  OSS2-4-8 cannot be used for rifampicin in 
steady state conditions.
Conclusion OSS at 2, 4 and 8 h post-dose enabled an accurate and precise prediction of AUC 24 values of first-line anti-TB 
drugs in this population.
Trial Registration ClinicalTrials.gov (NCT02121314).
Key Points 
Little information is available on sampling strategies 
in early TB treatment and in different conditions. This 
study investigated optimal sampling strategies (OSSs) to 
estimate area under the concentration–time curve from 
time zero to 24 h (AUC 24) of first-line anti-TB drugs in 
early treatment and in different conditions.
An OSS at 2, 4 and 8 h post-dose accurately predicted 
the AUC 24 of first-line anti-TB drugs in fasting and fed 
conditions in early treatment. These OSS equations sup-
port the therapeutic drug monitoring programmes aiming 
to personalize oral dosing for adult TB patients.
1 Introduction
Tuberculosis (TB) is a major problem worldwide. It is a cur-
able disease but, nevertheless, 1.7 million people died from TB 
in 2016 [1]. The reported treatment success rate for drug-sus-
ceptible TB ranges from 60 to 83% [1], meaning that health-
care providers encounter treatment failure in daily practice. 
The World Health Organization (WHO) aims to end the global 
TB epidemic by 2035 through several pillars and component 
goals, some of which are intensifying research and innova-
tion by the development of new strategies and optimization of 
implementation of treatment [1]. Optimization of treatment is 
imperative to increase the success rate of first-line treatment.
First-line treatment of TB consists of isoniazid, rifampicin, 
pyrazinamide and ethambutol for the first 2 months, followed 
by isoniazid and rifampicin for 4 months [2]. Clinical trials 
and observational studies have shown that low drug exposure 
of first-line drugs is associated with slow response to treat-
ment, acquired drug resistance, and relapse [3, 4].
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Several factors, such as malabsorption, pharmacogenet-
ics of N-acetyltransferase 2 (NAT2), intraindividual differ-
ences in pharmacokinetics (PK), or food intake, may lead 
to low drug exposure [4–6]. Treatment optimization can be 
achieved by increasing adherence [7] or studying new or 
repurposed drugs [8, 9]. Another option is better attainment 
of the pharmacokinetic/pharmacodynamic (PK/PD) param-
eters that best predict the efficacy of first-line anti-TB drugs, 
i.e. area under the concentration–time curve over 24 h (AUC 
24) divided by the minimal inhibitory concentration (MIC) 
[AUC/MIC ratio] [10]. However, actual MICs are often una-
vailable for first-line anti-TB drugs. Using classification and 
regression tree (CART) analysis, Pasipanodya et al. showed 
a clear concentration–effect relationship for the combination 
therapy of pyrazinamide, rifampicin and isoniazid [3].
Therapeutic drug monitoring (TDM), which measures drug 
exposure and adjusts the dose to optimize drug exposure, has 
been proposed to improve treatment response in individual TB 
patients, especially in patients at high risk of treatment failure 
or delayed response [11–14]. To calculate drug exposure, i.e. 
AUC 24, a full concentration–time curve should be obtained by 
sampling up to 10 times during the dosing interval. The bur-
den for both patients and the healthcare system hamper imple-
mentation in clinical practice [15, 16]. Therefore, there is an 
urgent need for alternative strategies to accurately estimate the 
AUC 24. A limited or optimal sampling strategy (OSS) might 
be the solution. This method calculates which time points 
during the dosing interval (usually one to three) are most 
informative for the accurate prediction of AUC 24 [14, 15].
Only a few studies in the literature have reported OSS for 
first-line anti-TB drugs [15–18]; however, these studies mostly 
addressed administration of a single drug [15, 17, 18] in the 
fasting condition [16–18], and no studies examined OSS in the 
early phase of treatment. Meanwhile, the number of bacilli was 
high in the early phase of treatment, thus the risk of acquired 
drug resistance was higher when drug exposure was inadequate 
[3]. One study described an OSS for multiple anti-TB drugs 
simultaneously, but, in that study, the time interval was limited 
to 6 h and was conducted in the fasting condition [16].
To overcome the limitations of currently available OSS, 
we aimed to develop an OSS in the early phase of treatment 
to estimate the AUC 24 of all first-line anti-TB drugs in fasting 
and fed conditions, as well as after intravenous administration.
2  Methods
2.1  Study Design, Population, and Pharmacokinetic 
Analysis
To develop the OSS, we used data from an earlier pub-
lished prospective, randomized, crossover PK study 
approved by the Institutional Review Board at the Faculty 
of Medicine, Public Health and Nursing, Universitas Gad-
jah Mada (UGM), Yogyakarta, Indonesia (KE/FK/626/
EC), and registered at ClinicalTrials.gov (NCT02121314) 
[19]. From November 2012 to March 2013, 20 newly diag-
nosed, treatment-naïve adults with drug-susceptible TB 
received isoniazid 5 mg/kg, rifampicin 10 mg/kg, etham-
butol 15 mg/kg and pyrazinamide 25 mg/kg. One patient 
was excluded from the study due to vomiting shortly after 
ingestion of the drugs on both days of oral treatment, and 
was replaced by inclusion of another subject. The study 
was performed on the first 3 days of anti-TB treatment. 
On day 1, all subjects received intravenous treatment of 
isoniazid (100 mg/mL injection; Department of Clinical 
Pharmacy and Pharmacology, University Medical Center 
Groningen (UMCG), Groningen, The Netherlands; license 
number 108964F), rifampicin (rifadin 600 mg injection; 
Sanofi Aventis, Guildford, UK) and ethambutol (EMB-
Fatol 1000 mg injection; Riemser Arzneimittel AG, Greif-
swald – Insel Riems, Germany). Isoniazid was adminis-
tered as a short infusion of 30 min, while rifampicin and 
ethambutol were infused over 2 h. Pyrazinamide was not 
available as an injection and was administered as a 500 mg 
tablet formulation (PT Indofarma, Bekasi, Indonesia) in a 
single oral dose on day 1.
Participants were randomly assigned to one of the 
two treatment groups (fasted day 2 and fed day 3, or fed 
day 2 and fasted day 3). On days 2 and 3, a fixed drug 
combination containing 75/150/275/400 mg of isoniazid, 
rifampicin, ethambutol and pyrazinamide (PT Indofarma) 
was administered orally. Serial blood samples were col-
lected at 0 (predose), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6 and 8 h 
after dosing, and were centrifuged and stored at −80 °C in 
the TB-Microbiology Laboratory of the Faculty of Medi-
cine, Public Health, and Nursing, UGM, Indonesia, until 
transported on dry ice to The Netherlands, with the provi-
sion of a Material Transfer Agreement (UGM–UMCG, 
and the National Agency of Food and Drug Control, Indo-
nesia; PN.01.06.1.31.11.12.7158). Plasma samples were 
analysed using validated liquid chromatography-tandem 
mass spectroscopy (LC–MS/MS) methods in the labora-
tory of the Department of Clinical Pharmacy and Phar-
macology of the UMCG, The Netherlands, as previously 
described [20, 21]. Concentrations at time points 0 on days 
2 and 3 also served as the 24-h concentration  (C24) on days 
1 and 2. The C24 on day 3 was calculated using the for-
mula C24 = Cmax × e−β×(24−Tmax), in which β is the first-order 
elimination rate constant,  Cmax is the maximum concentra-
tion measured, and Tmax is the time to reach Cmax. Plasma 
concentrations below the lower limit of quantification were 
treated as zero. The AUC 24,calculated was calculated using 
the log-linear trapezoidal rule in MW\Pharm (Kinfit, ver-
sion 3.60; Mediware, Groningen, The Netherlands); this 
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AUC 24,calculated represented the best approximation of the 
true AUC 24.
2.2  Optimal Sampling Strategies
We conducted multiple linear regression analysis to obtain 
optimal sampling equations predictive of the AUC 24 of 
each drug in the three different conditions. All possible 
combinations within the groups of one to three time points 
were evaluated, i.e. 11 combinations with one time point, 
55 combinations with two time points, and 165 combina-
tions with three time points. Assumptions of linear regres-
sion were assessed using R, i.e. normality of the dependent 
variable, linear relationship, error normality, multicollin-
earity and homoscedasticity.
Using best subset selection, we selected the best-per-
forming OSS for each drug and condition separately, for 
the simultaneous use of all drugs in each condition, and 
for the simultaneous use of all drugs after oral administra-
tion (either the fasting or fed condition). In addition, we 
tested the OSS from simultaneous prediction of the fasting 
and fed conditions following intravenous administration to 
examine whether the OSS was also suitable for application 
in intravenous administration.
The average adjusted R2 for all combinations compris-
ing one, two, or three samples were calculated to investi-
gate the correlation between the predicted AUC 24 (AUC 
24,predicted) using multiple linear regression and AUC 
24,calculated. With a time resolution of 1 h, the best OSS was 
selected based on the highest average adjusted  R2 com-
bined with an acceptable bias and precision.
2.3  Validation of the Optimal Sampling Strategy
To validate the OSS model, residuals for each patient were 
calculated using a jackknife analysis [16, 22]. All 20 patients 
were omitted, on a one-by-one basis, and the OSS using best 
subset selection was calculated for the 19 remaining patients 
in each scenario, as described above. The AUC 24,predicted and 
corresponding residuals were then calculated for the omit-
ted patient.
The following residuals were calculated. To assess poten-
tial bias in the predictions, the median prediction error 
(MPE) and median percentage prediction error (MPPE) were 
calculated. The MPE was converted into MPPE by dividing 
it by the AUC 24,calculated values [22–24]. To assess precision, 
root median squared prediction error (RMSE) and median 
absolute percentage prediction error (MAPE) were calcu-
lated [23, 25]. The equations used to calculate these four 
residuals were as follows [23]:
Bias
1. MPE: median (AUC 24,predicted − AUC 24,calculated)
2. MPPE: median [100% × (AUC 24,predicted − AUC 
24,calculated)/AUC 24,calculated]
Imprecision
1. RMSE: √median (AUC 24,predicted − AUC 24,calculated)2
2. MAPE: median [100% × I(AUC 24,predicted − AUC 
24,calculated)I/AUC 24,calculated]
OSS was considered acceptable if bias and imprecision 
were smaller than 5% and 15%, respectively [15, 16, 23].
A percentage prediction error (PPE), calculated as 
[100% × (AUC 24,predicted − AUC 24,calculated)/AUC 24,calculated], 
was used to show the performance of OSS equations from 
each individual [24, 26]. An acceptable PPE was considered 
smaller than 15% [24, 26], and the number of patients with 
a PPE < 15% was calculated for the best-performing OSS. 
Data analysis was carried out using R version 3.3.2 (The R 
Foundation, Austria, Vienna).
2.4  External Validation
To test whether the selected OSS was capable of predicting 
the AUC 24 in other patient groups, an external validation 
group was selected. This external validation group was the 
population in which Magis-Escurra et al. developed an OSS 
for the first-line drugs and also moxifloxacin. Study sub-
jects were TB patients admitted to the two Dutch TB referral 
centres, i.e. Radboud University Medical Centre, Nijmegen, 
Centre for Chronic Diseases Dekkerswald, Groesbeek, The 
Netherlands, and the UMCG, Tuberculosis Center Beat-
rixoord, Haren, The Netherlands. Forty-one adult patients 
were included after providing written informed consent. The 
included patients received isoniazid 5 mg/kg, rifampicin 
10 mg/kg, ethambutol 15 mg/kg and pyrazinamide 25 mg/
kg. A full PK curve was recorded during the intensive 
phase of TB treatment after steady state had been reached 
(≥ 2 weeks). Patients refrained from food intake from 23 h 
on the day preceding the PK assessment until 4 h after intake 
of the study medication. Serial venous blood samples were 
collected just prior to and at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 
and 24 h after witnessed intake of the study medication. 
Plasma was separated immediately, frozen at −80 °C and 
transported on dry ice for bioanalysis. Plasma concentrations 
of rifampicin, ethambutol and pyrazinamide were analysed 
at the University Medical Centre Nijmegen using validated 
high-performance liquid chromatography (HPLC) methods 
as described previously [27]. Plasma concentrations of iso-
niazid were determined at the UMCG using the validated 
LC–MS/MS method mentioned earlier [20]. The AUC 
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24,calculated was calculated using WinNonlin (further infor-
mation can be found in the original study [16]), while the 
AUC 24,predicted was calculated using the best-performing OSS 
formula in the fasting condition. For the external group, the 
same PPE < 15% was considered acceptable, and the number 
of patients with a PPE < 15% was calculated.
3  Results
Patient characteristics for both groups are presented in 
Table 1. The assumptions of linear regression for OSS 
analysis were fulfilled. Table 2 shows the best-performing 
one, two, and three time-point equations of the four first-line 
TB drugs individually when administered intravenously or 
in fasted or fed conditions. Only imprecision of the AUC 
prediction of ethambutol in the fed condition was higher 
than the preset limit of 15%. Table 3 presents the best-per-
forming equations for the simultaneous prediction of expo-
sure of all drugs when administered in different conditions, 
i.e. either intravenously or fasting or fed conditions. Again, 
only imprecision of ethambutol in the fed condition did not 
meet the requirements. The time points 0, 5, and 8 h post-
dose showed the best prediction for intravenous adminis-
tration of isoniazid, rifampicin and ethambutol. In the fed 
condition, sampling times at 1, 2 and 8 h post-dose were 
the best predictive factors, while in the fasting condition, 
sampling time points at 2, 4, and 8 h post-dose provided the 
best prediction.  
Table 4 shows the best-performing equations for simulta-
neous predictions of all first-line drugs administered orally, 
either in the fasting or fed condition. It can be observed that 
Table 1  Patient characteristics
Data are expressed as median (IQR) unless otherwise specified
Tested using the Mann–Whitney U test
OSS optimal sampling strategy, IQR interquartile range, BMI body mass index
a Tested using the Chi-square test
b Defined as BMI < 18.5 kg/m2
c n =35
Characteristic OSS group (n = 20) External validation group 
(n = 37)
P value
Male/female [n/n (%/ %)] 12/8 (60/40) 31/6 (84/16) <0.001a
Age, years 37.0 (24.0–51.8) 42.0 (30.0–56.5) 0.219
Bodyweight (kg) 41.5 (38.3–47.8) 64 (53.2–69.4) <0.001
BMI (kg/m2) 17.0 (15.9–19.1) 20.9 (18.1–23.6)c <0.001
Underweight [n (%)]b 14 (70) 11 (30) 0.500a
Ethnicity [n (%)] <0.001a
 Asian 20 (100) 5 (14)
 Black 0 (0) 12 (32)
 Caucasian 0 (0) 11 (30)
 Middle Eastern 0 (0) 5 (14)
 Other/mixed origin 0 (0) 4 (11)
Comorbidity [n (%)] 4 (20) 14 (38) 0.005a
Comedication [n (%)] 8 (40) 29 (78) 0.024a
Drug
 Isoniazid (n) 20 8 0.263
 Dose (mg/kg) 5.4 (4.7–5.7) 4.7 (4.2–5.8)
 Dose (mg) 225 (225–225) 300 (300–300)
 Rifampicin (n) 20 31 0.070
 Dose (mg/kg) 10.7 (9.5–11.4) 9.3 (8.6–11.0)
 Dose (mg) 450 (450–450) 600 (600–600)
 Ethambutol (n) 20 14 0.119
 Dose (mg/kg) 19.6 (17.3–20.9) 20.3 (18.7–23.6)
 Dose (mg) 825 (825–825) 1200 (1000–1600)
 Pyrazinamide (n) 20 17 0.647
 Dose (mg/kg) 28.6 (25.1–30.4) 28.8 (27.9–29.6)
 Dose (mg) 1200 (1200–1200) 2000 (1500–2000)
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after oral administration,  C2,  C4 and  C8 are nicely distributed 
over the absorption, distribution and elimination phase, lead-
ing to an adequate AUC 24 estimation. The bias and impreci-
sion were acceptable for almost all drugs. We did not calculate 
the best OSS combined for all three conditions because cli-
nicians will only occasionally combine oral and intravenous 
administrations. However, when we tested this best-perform-
ing OSS  (OSS2-4-8) following intravenous administration, we 
found that this OSS showed bias and imprecision that was 
comparable with  OSS0-5-8, indicating that it was also suitable 
for accurately estimating the AUC 24 for intravenous isoniazid, 
rifampicin and ethambutol (Table 3). Thus,  OSS2-4-8 can be 
used for either oral or intravenous administration.
Table  5 shows the median PPE (range) and number 
of patients with a PPE < 15%. We showed that ≥ 70% of 
patients in the OSS group (for all drugs and oral conditions) 
had an acceptable PPE value, except for ethambutol in the 
fed condition. In the external validation group,  OSS2-4-8 
could correctly predict 79% and 88% of the individual 
AUC 24 of ethambutol and pyrazinamide, respectively, but in 
only 50% and 23% of the individual AUC 24 of isoniazid and 
rifampicin, respectively.
Table 2  Prediction of individual first-line tuberculosis drugs in different conditions
MPE median prediction error, MPPE median percentage prediction error, RMSE root median squared prediction error, MAPE median abso-
lute percentage prediction error, AUC24 area under the concentration–time curve from time zero to 24  h, Adj. adjusted, INH isoniazid, RIF 
rifampicin, EMB ethambutol, PZA pyrazinamide, IV intravenously
Sampling time Equation Adj. R2 MPE MPPE (%) RMSE MAPE (%)
INH IV 5 AUC 24 = 5.08 + 12.27 × C5 0.8929 −0.58 −4.53 1.69 8.95
2, 8 AUC 24 = − 0.12 + 4.32 × C2 + 10.30 × C8 0.9313 0.04 0.34 1.92 11.46
2, 3, 8 AUC 24 = − 0.59 + 7.34 × C2 − 5.39 × C3 + 14.90 × C8 0.9358 0.14 1.70 2.43 13.44
Fasted 8 AUC 24 = 8.19 + 13.81 × C8 0.9148 −0.61 −4.65 1.86 11.52
1, 8 AUC 24 = 5.39 + 0.93 × C1 + 12.75 × C8 0.9378 0.31 1.88 1.46 9.53
1, 6, 8 AUC 24 = 4.87 + 1.59 × C1 − 6.82 × C6 + 19.47 × C8 0.9625 0.49 1.71 1.41 11.46
Fed 8 AUC 24 = 3.25 + 16.13 × C8 0.8330 0.65 6.42 3.52 23.60
2, 8 AUC 24 = − 1.45 + 2.61 × C2 + 14.99 × C8 0.9528 −0.09 −2.25 1.72 14.09
1, 2, 8 AUC 24 = − 1.28 + 1.00 × C1 +1.93 × C2 + 15.05 × C8 0.9638 −0.44 −2.53 1.19 7.90
RIF IV 8 AUC 24 = − 1.02 + 18.94 × C8 0.9402 −1.60 −1.77 4.60 6.71
1, 8 AUC 24 = − 8.37 + 1.15 × C1 + 18.23 × C8 0.9541 −1.14 −1.31 5.96 6.37
1, 5, 8 AUC 24 = − 2.25 + 1.24 × C1 − 5.61 × C5 + 25.01 × C8 0.9622 −1.38 −1.52 5.50 5.91
Fasted 8 AUC 24 = − 5.38 + 18.91 × C8 0.8501 −2.24 −5.15 7.87 9.46
2, 8 AUC 24 = 11.78 + 1.76 × C2 + 16.73 × C8 0.8823 −1.44 −1.48 3.46 6.23
2, 5, 8 AUC 24 = − 2.95 + 2.29 × C2 − 4.88 × C5 + 20.97 × C8 0.9026 −0.19 −0.39 4.04 6.61
Fed 8 AUC 24 = 2.02 + 14.30 × C8 0.8373 1.14 3.04 8.11 11.20
2, 8 AUC 24 = − 9.67 + 2.10 × C2 + 14.76 × C8 0.9605 −1.18 −1.31 2.56 4.59
2, 3, 8 AUC 24 = − 15.18 + 1.58 × C2 + 0.99 × C3 + 15.05 × C8 0.9636 −0.89 −1.14 5.10 7.90
EMB IV 6 AUC 24 = − 1.96 + 27.75 × C6 0.7856 −0.65 −3.54 1.62 13.96
0, 8 AUC 24 = − 2.96–19.86 × C0 + 41.52 × C8 0.8364 −0.32 −3.13 2.30 14.77
0, 5, 8 AUC 24 = − 4.67–21.39 × C0 +13.65 × C5 + 22.41 × C8 0.9105 0.11 0.73 1.50 10.80
Fasted 8 AUC 24 = 2.75 + 17.67 × C8 0.7332 −0.19 −1.37 2.24 14.19
2, 8 AUC 24 = 0.19 + 1.30 × C2 + 17.61 × C8 0.8019 0.51 3.77 2.25 14.46
2, 4, 8 AUC 24 = − 1.74 + 1.09 × C2
+2.29 × C4 + 15.05 × C8
0.8445 0.43 3.30 2.18 12.91
Fed 8 AUC 24 = 6.57 + 10.74 × C8 0.3755 0.13 1.02 3.90 28.14
2, 8 AUC 24 = − 2.01 + 3.54 × C2 + 13.98 × C8 0.5698 −0.23 −1.96 2.34 17.51
1, 2, 8 AUC 24 = − 2.14-3.02 × C1 +4.86 × C2 + 13.77 × C8 0.5814 −0.38 −2.44 2.82 18.13
PZA Fasted 8 AUC 24 = − 24.64 + 20.33 × C8 0.9689 −0.66 −0.16 12.35 3.27
5, 8 AUC 24 = − 42.50 + 3.83 × C5 + 16.38 × C8 0.9731 −2.39 −0.36 12.02 2.29
0, 5, 8 AUC 24 = 4.78 × C0 + 4.47 × C5 + 13.96 × C8 0.9752 0.02 0.02 11.75 3.02
Fed 8 AUC 24 = 4.98 + 17.79 × C8 0.8868 0.95 0.19 27.39 6.73
2, 8 AUC 24 = − 28.69 + 2.60 × C2 + 15.83 × C8 0.9454 1.89 0.58 19.34 3.68
0, 2, 8 AUC 24 = − 17.07 + 8.34 × C0 +2.81 × C2 + 13.20 × C8 0.9710 0.73 0.16 15.28 2.81
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4  Discussion
To our knowledge, this is the first study to develop an OSS 
for the prediction of AUC 24 of first-line anti-TB drugs in 
early treatment and in different conditions.  OSS2-4-8 accu-
rately estimated AUC 24 for first-line anti-TB drugs after oral 
administration in early treatment.
If we compare our data with the only study that described 
an OSS for all first-line anti-TB drugs, several differences 
can be observed (Table 6) [16]. Apart from the differences 
already mentioned in the Introduction on feeding conditions 
and time restrictions, the earlier study included a more vari-
able population with regard to ethnicity and patients from 
referral TB centres. Meanwhile, in this study, we included 
only regular outpatients of Asian ethnicity (Table 1).
With regard to isoniazid, Cojutti et al. determined and 
validated an OSS at 1, 2 and 9 h after dosing in a large popu-
lation, consisting of 100 patients for the modelling group 
Table 3  Simultaneous prediction of all first-line tuberculosis drugs in different conditions
MPE median prediction error, MPPE median percentage prediction error, RMSE root median squared prediction error, MAPE median abso-
lute percentage prediction error, AUC24 area under the concentration–time curve from time zero to 24  h, Adj. adjusted, INH isoniazid, RIF 
rifampicin, EMB ethambutol, PZA pyrazinamide, IV intravenously
Sampling time Equation Adj.  R2 MPE MPPE (%) RMSE MAPE (%)
IV 5 INH AUC 24 = 5.08 + 12.27 × C5 0.8929 −0.58 −4.53 1.69 8.95
RIF AUC 24 = − 9.52 + 14.08 × C5 0.8228 −2.86 −3.59 9.53 10.08
EMB AUC 24 = − 2.06 + 22.74 × C5 0.7799 −0.59 −4.20 1.81 15.58
2, 8 INH AUC 24 = − 0.12 + 4.32 × C2 + 10.30 × C8 0.9313 0.04 0.34 1.92 11.46
RIF AUC 24 = − 5.34 + 0.66 × C2 + 18.27 × C8 0.9385 −2.46 −3.25 5.11 5.74
EMB AUC 24 = − 1.32 + 1.21 × C2 + 27.59 × C8 0.7961 −0.93 −8.72 2.14 15.07
0, 5, 8 INH AUC 24 = 4.62 + 1.21 × C0 +14.00 × C5 + 2.74 × C8 0.8825 −0.62 −3.27 1.68 14.38
RIF AUC 24 = 6.80 + 7.56 × C0
−5.69 × C5 + 25.58 × C8
0.9408 −1.87 −2.43 5.67 7.59
EMB AUC 24 = − 4.67–21.39 × C0 +13.65 × C5 + 22.41 × C8 0.9105 0.11 0.73 1.50 10.80
2, 4, 8 INH AUC 24 = − 1.10 + 5.59 × C2 − 3.00 × C4 + 13.07 × C8 0.9308 −0.10 −0.71 1.97 9.44
RIF AUC 24 = − 1.43 + 0.96 × C2 − 2.75 × C4 + 21.22 × C8 0.9395 −2.34 −2.59 4.34 4.79
EMB AUC 24 = − 3.10 + 1.22 × C2 + 7.80 × C4 + 14.24 × C8 0.8128 −0.97 −7.26 1.68 12.03
Fasted 8 INH AUC 24 = 8.19 + 13.81 × C8 0.9148 −0.61 −4.65 1.86 11.52
RIF AUC 24 = − 5.38 + 18.91 × C8 0.8501 −2.24 −5.15 7.87 9.46
EMB AUC 24 = 2.75 + 17.67 × C8 0.7332 −0.19 −1.37 14.12 14.19
PZA AUC 24 = − 24.64 + 20.33 × C8 0.9689 −0.66 −0.16 2.48 3.27
2, 8 INH AUC 24 = 4.83 + 1.41 × C2 + 11.71 × C8 0.9217 −0.69 −3.17 1.72 14.70
RIF AUC 24 = − 11.78 + 1.76 × C2 + 16.73 × C8 0.8823 −1.44 −1.48 3.46 6.23
EMB AUC 24 = 0.19 + 1.30 × C2 + 17.61 × C8 0.8019 0.51 3.77 14.19 14.46
PZA AUC 24 = − 36.04 + 0.89 × C2 + 19.35 × C8 0.9684 −1.73 −0.40 2.05 2.63
2, 4, 8 INH AUC 24 = 3.81 + 2.99 × C2 − 4.74 × C4 + 17.08 × C8 0.9401 −0.67 −4.75 1.75 11.59
RIF AUC 24 = − 4.00 + 2.16 × C2 − 2.21 × C4 + 17.90 × C8 0.8861 −0.66 −0.86 4.64 8.88
EMB AUC 24 = − 1.74 + 1.09 × C2 + 2.29 × C4 + 15.05 × C8 0.8445 0.43 3.30 13.75 12.91
PZA AUC 24 = − 34.77 + 1.08 × C2 − 0.58 × C4 + 19.76 × C8 0.9666 −1.21 −0.18 2.76 3.19
Fed 8 INH AUC 24 = 3.25 + 16.13 × C8 0.8330 0.65 6.42 3.52 23.60
RIF AUC 24 = 2.02 + 14.30 × C8 0.8373 1.14 3.04 8.11 11.20
EMB AUC 24 = 6.57 + 10.74 × C8 0.3755 0.13 1.02 3.90 28.14
PZA AUC 24 = 4.98 + 17.79 × C8 0.8868 0.95 0.19 5.83 6.73
2, 8 INH AUC 24 = − 1.45 + 2.61 × C2 + 14.99 × C8 0.9528 −0.09 −2.25 1.72 14.09
RIF AUC 24 = − 9.67 + 2.10 × C2 + 14.76 × C8 0.9605 −1.18 −1.31 2.56 4.59
EMB AUC 24 = − 2.01 + 3.54 × C2 + 13.98 × C8 0.5698 −0.23 −1.96 2.34 17.51
PZA AUC 24 = − 28.69 + 2.60 × C2 + 15.83 × C8 0.9454 1.89 0.58 4.12 3.68
1, 2, 8 INH AUC 24 = − 1.28 + 1.00 × C1 + 1.93 × C2 + 15.05 × C8 0.9638 −0.44 −2.53 1.19 7.90
RIF AUC 24 = − 9.77–0.08 × C1 + 2.13 × C2 + 14.78 × C8 0.9581 −1.18 −1.31 2.81 4.53
EMB AUC 24 = − 2.14–3.02 × C1 + 4.86 × C2 + 13.77 × C8 0.5814 −0.38 −2.44 2.82 18.13
PZA AUC 24 = − 24.71 + 1.06 × C1 + 1.75 × C2 + 15.94 × C8 0.9521 −2.47 −0.50 16.31 4.17
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and 85 for the validation group [17] (Table 6). Our proposed 
time point of 8 h post-dose is comparable with that of Cojutti 
et al., indicating that a rather late time point is capable of 
better predicting AUC 24 [17]. In another publication by the 
same group, a threshold of 55 mg × h/L for toxicity of isonia-
zid has been proposed [28]. In none of our patients, in either 
the OSS or external validation groups, was such a high AUC 
24 observed, possibly due to the fact that the majority of the 
included patients were fast acetylators.
Rifampicin shows auto-induction that is complete 
after 20–30  days [29]. Auto-induction might influence 
the OSS as PK properties may change. This was indeed 
shown in our OSS group experiencing a higher AUC 
24 (range 36–129 mg × h/L) than AUC 24 in steady-state 
patients [16]. However, the AUC 24 was not in the range 
(166–321 mg × h/L) of the high dose rifampicin, i.e. up to 
35 mg/kg [30]. The external validation using steady-state 
patients did not succeed for rifampicin as the majority of 
patients showed a PPE > 15% (Table 5). It is apparently 
difficult to predict the complex PK of rifampicin based on 
early measurements. For this drug, we suggest using an OSS 
based on a population PK model [15].
Regarding the internal jackknife validation, the prediction 
of ethambutol was the most difficult and  OSS2-4-8 was unable 
to accurately predict a high percentage of individual AUCs 
(Table 5). However, TDM of ethambutol is rarely performed, 
and if performed, it is usually in cases of decreased renal 
function, trying to limit toxicity [11]. Following on from 
this, ethambutol is mainly used to prevent the emergence 
of resistance developing for isoniazid and rifampicin. We 
believe the lower precision in the prediction of AUC 24 of 
ethambutol is acceptable in daily practice. It was striking 
that  OSS2-4-8 predicted AUC 24 of ethambutol rather well in 
the external validation group (Table 5).
The AUC 24 of pyrazinamide has not been linked to toxic-
ity [31]. Although the relationship between pyrazinamide 
dose and hepatotoxicity remains debatable, it appears that 
doses over 50 mg/kg may compromise patient safety. Cur-
rent dosing of pyrazinamide also appears to be on the lower 
side of effective [32].  OSS2-4-8 well-predicted the AUC 24 of 
pyrazinamide in the external validation group, although the 
Table 4  Simultaneous prediction of all first-line tuberculosis drugs in fasting and fed conditions
MPE median prediction error, MPPE median percentage prediction error, RMSE root median squared prediction error, MAPE median abso-
lute percentage prediction error, AUC24 area under the concentration–time curve from time zero to 24  h, Adj. adjusted, INH isoniazid, RIF 
rifampicin, EMB ethambutol, PZA pyrazinamide
Sampling time Equation Adj.  R2 MPE MPPE (%) RMSE MAPE (%)
INH 8 Fasted AUC 24 = 8.19 + 13.81 × C8 0.9149 −0.61 −4.65 1.86 11.52
Fed AUC 24 = 3.25 + 16.13 × C8 0.8330 0.65 6.42 3.52 23.60
2, 8 Fasted AUC 24 = 4.83 + 1.41 × C2 + 11.71 × C8 0.9218 −0.69 −3.17 1.72 14.70
Fed AUC 24 = − 1.45 + 2.61 × C2 + 14.99 × C8 0.9528 −0.09 −2.25 1.72 14.09
2, 4, 8 Fasted AUC 24 = 3.81 + 2.99 × C2 − 4.74 × C4 + 17.08 × C8 0.9401 −0.67 −4.75 1.75 11.59
Fed AUC 24 = − 2.71 + 2.36 × C2 +2.28 × C4 + 12.21 × C8 0.9581 −0.16 1.49 1.53 11.37
RIF 8 Fasted AUC 24 = − 5.38 + 18.91 × C8 0.8501 −2.24 −5.15 7.87 9.46
Fed AUC 24 = 2.02 + 14.30 × C8 0.8373 1.14 3.04 8.11 11.20
2, 8 Fasted AUC 24 = − 11.78 + 1.76 × C2 + 16.73 × C8 0.8823 −1.44 −1.48 3.46 6.23
Fed AUC 24 = − 9.67 + 2.10 × C2 + 14.76 × C8 0.9605 −1.18 −1.31 2.56 4.59
2, 4, 8 Fasted AUC 24 = − 4.00 + 2.16 × C2 − 2.21 × C4 + 17.90 × C8 0.8861 −0.66 −0.86 4.64 8.88
Fed AUC 24 = − 14.57 + 1.80 × C2 + 1.03 × C4 + 14.55 × C8 0.9625 −0.42 −0.52 2.78 6.60
EMB 8 Fasted AUC 24 = 2.75 + 17.66 × C8 0.7333 −0.19 −1.37 2.24 14.19
Fed AUC 24 = 6.57 + 10.74 × C8 0.3755 0.13 1.02 3.90 28.14
2, 8 Fasted AUC 24 = 0.19 + 1.30 × C2 + 17.61 × C8 0.8019 0.51 3.77 2.25 14.46
Fed AUC 24 = − 2.01 + 3.54 × C2 + 13.98 × C8 0.5698 −0.23 −1.96 2.34 17.51
2, 4, 8 Fasted AUC 24 = − 1.74 + 1.08 × C2 + 2.29 × C4 + 15.05 × C8 0.8445 0.43 3.30 2.18 12.91
Fed AUC 24 = − 2.76 + 3.33 × C2 + 1.04 × C4 + 12.79 × C8 0.5512 0.20 0.60 2.63 20.67
PZA 8 Fasted AUC 24 = − 24.64 + 20.33 × C8 0.9689 −0.66 −0.16 12.35 3.27
Fed AUC 24 = 4.98 + 17.79 × C8 0.8868 0.95 0.19 27.39 6.73
2, 8 Fasted AUC 24 = − 36.04 + 0.89 × C2 + 19.35 × C8 0.9684 −1.73 −0.40 10.20 2.63
Fed AUC 24 = − 28.69 + 2.60 × C2 + 15.83 × C8 0.9454 1.89 0.58 19.34 3.68
2, 4, 8 Fasted AUC 24 = − 34.77 + 1.08 × C2 − 0.58 × C4 + 19.76 × C8 0.9666 −1.21 −0.18 13.74 3.19
Fed AUC 24 = − 2.34 + 3.13 × C2 − 2.91 × C4 + 18.07 × C8 0.9485 −0.27 −0.11 21.32 4.28
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drug had not reached steady state in the first 3 days of treat-
ment. Therefore,  OSS2-4-8 can be used to estimate the AUC 
24 of pyrazinamide in other patient groups.
We calculated linear regression equations for OSS for 
all time points included in the study, for one to three time 
points, leading to 231 equations per drug and condition. Sev-
eral equations are comparable in terms of bias and precision 
and can be used with the same extent of confidence. To be 
able to widely implement TDM, it would be beneficial to 
make all equations electronically available, e.g. in an appli-
cation (app). The user would easily calculate the AUC 24 by 
entering data regarding sampling times, concentration, type 
of drugs, administration route and condition.
There are several limitations to this study. Although the 
sample size can be considered standard for intensive PK 
studies, it was relatively small for an OSS study. To calculate 
the AUC 24,calculated, a limited number of samples were drawn 
in the elimination phase of the drugs, possibly resulting in 
an over- or underestimation of the true AUC 24. We believe 
this deviation is acceptable as rich sampling, especially in the 
elimination phase, is hardly ever performed in daily practice. 
We internally validated the OSS equations using the jack-
knife method instead of a prospective validation with new 
subjects. However, this method is appropriate for small sam-
ple sizes and effectively eliminates the major influence of a 
particular subject [22]. The number of patients (n =8) in the 
external validation group for isoniazid was too small to draw 
a conclusion on the external validity of  OSS2-4-8. One might 
argue that OSS should have been developed using validated 
population PK models. In our opinion, both strategies have 
Table 5  Median percentage prediction error (range) and number of patients (%) with a PPE < 15% for OSS and external validation groups
PPE percentage prediction error, OSS optimal sampling strategy, NA not applicable
Condition OSS2-4-8 equation OSS group External validation group
PPE  % [median 
(range)]
No. of patients 
with PPE < 15% 
(%)
PPE  % [median (range)] No. of patients 
with PPE < 15% 
(%)
Isoniazid
Fasted 3.81 + 2.99 × C2 − 4.74 × C4 + 17.08 × C8 9.8 (0.1–40.7) 14/20 (70) 14.7 (4.7–28.9) 4/8 (50)
Fed −2.71 + 2.36 × C2 + 2.28 × C4 + 12.21 × C8 9.3 (0.5–46.6) 16/20 (80) NA NA
Rifampicin
Fasted −4.00 + 2.16 × C2 − 2.21 × C4 + 17.90 × C8 7.6 (0.0–36.3) 18/20 (90) 38 (2.1–108.2) 7/31 (23)
Fed −14.57 + 1.80 × C2 + 1.03 × C4 + 14.55 × C8 5.8 (0.0–26.8) 16/20 (80) NA NA
Ethambutol
Fasted −1.74 + 1.09 × C2 + 2.29 × C4 + 15.05 × C8 10.7 (2.8–21.8) 14/20 (70) 12 (1.4–66.7) 11/14 (79)
Fed −2.76 + 3.33 × C2 + 1.04 × C4 + 12.79 × C8 13.5 (0.7–166.2) 11/20 (55) NA NA
Pyrazinamide
Fasted −34.77 + 1.08 × C2 − 0.58 × C4 + 19.76 × C8 2.4 (0.1–10.6) 20/20 (100) 4.2 (0.1–41.7) 15/17 (88)
Fed −2.34 + 3.13 × C2 − 2.91 × C4 + 18.07 × C8 3.4 (0.1–9.5) 20/20 (100) NA NA
Table 6  Other optimal sampling 
strategy studies
M modelling, V validation, OSS optimal sampling strategy, AUC24 area under the concentration–time 
curve from time zero to 24 h, PK pharmacokinetic









2-4-6 (−1.46 + 1.18 × C2 + 4.71 × C4 + 5.51 × C6)
2-4-6 (−2.22 + 2.05 × C2 + 2.25 × C4 + 4.93 × C6)
2-4-6 (−48.65 + 1.78 × C2 + 3.58 × C4 + 9.90 × C6)
2-4-6 (−6.34 + 5.22 × C2 + 2.83 × C4 + 7.07 × C6)





1-2-5 (−1.88 + 1.05 × C1 + 0.78 × C2 + 9.44 × C5)
1-2-9 (−0.65 + 1.00 × C1 + 1.94 × C2 + 15.45 × C9)
0.5-2-12 (0.55 + 0.76 × C0.5 + 3.15 × C2 + 19.79 × C12)
Fasting steady state






2-4-12 (−2.47 + 1.92 × C2 + 4.38 × C4 + 13.7 × C12) Fasting steady state
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advantages and disadvantages. A Bayesian approach using 
a population PK model is more flexible, allowing for devia-
tions from the exact sampling times. A disadvantage is the 
use of software and use of the model, whereas multiple linear 
regression formulas yield straightforward equations to fill in 
[15]. Lastly, sampling took place in the first 3 days of treat-
ment, thus none of the drugs reached steady state. However, 
we believe that performing TDM early on in the treatment 
phase could be of importance for isoniazid as this drug is 
most active in the first 3 days of treatment because of its high 
early bactericidal activity [33]. If one waits until steady state, 
precious time is missed to optimize isoniazid treatment [17].
5  Conclusions
In the early days of TB treatment, an OSS at 2, 4 and 8 h 
post-dose adequately predicted the AUC 24 of first-line anti-
TB drugs in fasting or fed conditions. The external validation 
group for isoniazid was too small to draw a conclusion, and, 
for rifampicin, showed that  OSS2-4-8 was unable to accurately 
predict AUC 24 in patients in the steady state phase of treat-
ment.  OSS2-4-8 was able to predict the AUC 24 of ethambutol 
and pyrazinamide with sufficient accuracy and precision. We 
believe that our OSS strategy may be a useful tool for opti-
mizing exposure of first-line anti-TB drugs, although well-
defined PK/PD targets of efficacy or toxicity are still lacking.
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